A surge of federal warnings about addictive prescription painkillers and a flood of discounted competitors has hit Endo Pharmaceuticals hard, and the Irish-owned but Malvern-run generic drug giant is feeling the pain big time in the wake of a 40 percent one-day stock price plummet on Friday.

“Things have gone very bad very quickly,” JPMorgan analyst Christopher Schott said in a Philly.com report by Joseph N. DiStefano.

Endo announced Thursday that it will restructure its manufacturing operations and cut 740 out-of-state employees in light of a $133.9 million first-quarter loss, another Philly.com report by Linda Loyd stated.

“As we move further into 2016, we are rebasing our full-year financial expectations due to the impact of several previously unanticipated headwinds: new competitive entrants, including for Voltaren Gel; greater than expected price erosion across the generics sector; and delays on regulatory actions related to certain Endo products,” President and CEO Rajiv De Silva said in the latter article.

The stock market response, the company’s third-largest selloff, hit Endo with an additional loss of $2.3 billion from its market valuation, a Daily Local News staff report stated.

Read more about Endo’s first quarter results and investor reactions on Philly.com here and here, and in the Daily Local News here. Then check out previous VISTA Today coverage of the pharmaceutical leader here.